肿瘤细胞治疗研究
MODALITY HUB
FOR TREATMENT
现在就能报名的(招募中)排在最前,共 1 项。同一状态内中国中心优先。信息来自 ClinicalTrials.gov、CDE 与 ChiCTR 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
Platelet-engineered CAR-T cells as adjuvant therapy after cancer surgery.
New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo.
MEMBER ACCOUNT
登录成功会直接打开下一页。